Antitumoral activity of a xanthate compound. I. Cytotoxicity studies with neoplastic cell lines in vitro.
Xanthate derivatives were shown previously to display antitumor activity against transformed fibroblasts and lymphoma cells in combination with monocarboxylic acids [1]. Various malignant cell lines of human origin were treated in vitro to explore the range of antitumoral activity of the compounds. The combination of tricyclodecan-9-yl-xanthogenate (D 609) with undecanoic acid (C11) exerted dose dependent cytotoxic and antiproliferative effects on cell lines both from solid tumors (glioblastomas, colon-carcinomas) and hematological diseases (lymphomas, CML/BC). Additionally, the combination of D 609/C11 was able to kill both methotrexate- and adriamycin-resistant L 1210 and S 180 cells, indicating that there is no cross-resistance for these drugs and D 609/C11 in vitro.
Schick
H D
HD
Department of Medicine I, Technische Universität, Munich, F.R.G.
Amtmann
E
E
Berdel
W E
WE
Danhauser-Riedl
S
S
Reichert
A
A
Steinhauser
G
G
Rastetter
J
J
Sauer
G
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D004351:Drug Resistance; D005227:Fatty Acids / Q000008:administration & dosage; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009636:Norbornanes; D013859:Thiocarbamates; D013871:Thiones / Q000008:administration & dosage; D014407:Tumor Cells, Cultured
D001952:Bridged-Ring Compounds; D005227:Fatty Acids; D009636:Norbornanes; D013859:Thiocarbamates; D013871:Thiones; C016173:undecanoic acid; C046498:tricyclodecane-9-yl-xanthogenate